Synergys is an early stage  company focusing on the development of a portfolio of targeted antibody fusion candidates for cancer treatment. The most advanced product candidate of the Company is a first-in-class combined vasculogenic mimicry-blocking and angiogenesis-inhibitory antibody fusion molecule that is highly differentiated from the currently marketed anti-angiogenic antibody products. This  is initially being developed for the treatment of Triple Negative Breast Cancer (TNBC).  A second fusion candidate from this portfolio is an anti-Her2 fusion  that is being targeted for metastatic ovarian cancer patients.

 

The Company is strategically located in the top biotechnology cluster of the nation, in the San Francisco Bay area. Our management and advisory team members are veterans of  antibody field spanning more than 25 years of average experience covering both product development and business operations. Our Scientific Board Members include world-renowned cancer scientists and clinical oncology experts.

 

  “Wherever the art of Medicine is loved, there is also a love of Humanity". 

                                                                                         ― Hippocrates